Lewis Y regulates signaling molecules of the transforming growth factor β pathway in ovarian carcinoma-derived RMG-I cells

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 1196-1202

  Li, Fei Fei ^a,b   Liu, Juan Juan ^a   Liu, Da Wo ^a   Lin, Bei ^a   Hao, Ying Ying ^a   Cong, Jian Ping ^a   Zhu, Lian Cheng ^a   Gao, Song ^a   Zhang, Shu Lan ^a   Iwamori, Masao ^c  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c KINKI UNIVERSITY   (Japan)

Author keywords

Lewis Y; P42 44 mitogen activated protein kinase; Phosphoinositide 3 kinase; Smad; Transforming growth factor type I (II) receptor

Indexed keywords

FUCOSYLTRANSFERASE; LEWIS Y; MITOGEN ACTIVATED PROTEIN KINASE; OLIGOSACCHARIDE; PHOSPHATIDYLINOSITOL 3 KINASE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER THERAPY; CARBOHYDRATE SYNTHESIS; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; HUMANS; LEWIS BLOOD-GROUP SYSTEM; MICE; MICE, INBRED BALB C; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84863372049     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1296     Document Type: Article

References (44)

1. Baldus SE, Mönig SP, Zirbes TK, et al: Lewis(y) antigen (CD174) and apoptosis in gastric and colorectal carcinomas: correlations with clinical and prognostic parameters. Histol Histopathol 21: 503-510, 2006.
2. Kuemmel A, Single K, Bittinger F, et al: The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer. Tumour Biol 28: 340-349, 2007. (Pubitemid 351567552)
3. Chhieng DC, Rodriguez-Burford C, Talley LI, et al: Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma. Hum Pathol 34: 1016-1021, 2003. (Pubitemid 37315253)
4. Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I and Durrant LG: High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res 7: R780-R787, 2005.
5. Iwamori M, Tanaka K, Kubushiro K, et al: Alterations in the glycolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the α1,2-fucosyltransferase gene. Cancer Sci 96: 26-30, 2005. (Pubitemid 40310021)
6. Lin B, Hao YY, Wang DD, Zhu LC, Zhang SL, Saito M and Iwamori M: Transfection of α1,2-fucosyltransferase gene increases the antigenic expression of Lewis y in ovarian cancer cell line RMG-I. Acta Acad Med Sin 30: 284-289, 2008.
7. Hao YY, Lin B, Zhao Y, et al: Alpha1,2-fucosyltransferase gene transfection influences on biological behavior of ovarian carcinoma-derived RMG-I cells. Fen Zi Xi Bao Sheng Wu Xue Bao 41: 435-442, 2008.
8. Liu J, Lin B, Hao Y, et al: Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway. J Exp Clin Cancer Res 28: 154, 2009.
9. Li F, Lin B, Hao Y, et al: Lewis y promotes growth and adhesion of ovarian carcinoma-derived RMG-I cells by upregulating growth factors. Int J Mol Sci 11: 3748-3759, 2010.
10. Wang X, Inoue S, Gu J, et al: Dysregulation of TGF-β1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc Natl Acad Sci USA 102: 15791-15796, 2005. (Pubitemid 41552821)
11. Zhu LC, Lin B, Hao YY, Li FF, Diao B and Zhang SL: Impact of α1,2-fucosyltransferase gene transfection on cancer-related gene expression profile of human ovarian cancer cell line RMG-1. Ai Zheng 27: 934-941, 2008.
12. Basu A, Murthy U, Rodeck U, Herlyn M, Mattes L and Das M: Presence of tumor-associated antigens in epidermal growth factor receptors from different human carcinomas. Cancer Res 47: 2531-2536, 1987. (Pubitemid 17083135)
13. Klinger M, Farhan H, Just H, et al: Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res 64: 1087-1093, 2004. (Pubitemid 38176914)
14. Kosunen TU, Bång BE and Hurme M: Analysis of Campylobacter jejuni antigens with monoclonal antibodies. J Clin Microbiol 19: 129-133, 1984. (Pubitemid 14183562)
15. Bång BE, Hurme M, Juntunen K and Mäkelä O: Studies of monoclonal and polyclonal anti-digoxin antibodies for serum digoxin radioimmunoassay. Scand J Clin Lab Invest 41: 75-78, 1981.
16. Moran AP, Knirel YA, Senchenkova SN, Widmalm G, Hynes SO and Jansson PE: Phenotypic variation in molecular mimicry between Helicobacter pylori lipopolysaccharides and human gastric epithelial cell surface glycoforms. Acid-induced phase variation in Lewisx and Lewisy expression by H. pylori lipopolysaccharides. J Biol Chem 277: 5785-5795, 2002. (Pubitemid 34968356)
17. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
18. Yu L, Hebert MC and Zhang YE: TGF-β receptor-activated p38 MAP kinase mediates Smad-independent TGF-β responses. EMBO J 21: 3749-3759, 2002. (Pubitemid 34787048)
19. Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature 425: 577-584, 2003. (Pubitemid 37280136)
20. Wilkes MC, Mitchell H, Penheiter SG, et al: Transforming growth factor-β activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res 65: 10431.-10440, 2005.
21. Zhang YE: Non-Smad pathways in TGF-β signaling. Cell Res 19: 128-139, 2009.
22. Pasche B: Role of transforming growth factor beta in cancer. J Cell Physiol 186: 153-168, 2001.
23. Elliott RL and Blobe GC: Role of transforming growth factor beta in human cancer. J Clin Oncol 23: 2078-2093, 2005. (Pubitemid 46211385)
24. Tian M and Schiemann WP: The TGF-β paradox in human cancer: an update. Future Oncol 5: 259-271, 2009.
25. Fynan TM and Reiss M: Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncol 4: 493-540, 1993.
26. Massague J, Blain SW and Lo RS: TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309, 2000.
27. Yamada SD, Baldwin RL and Karlan BY: Ovarian carcinoma cell cultures are resistant to TGF-β1-mediated growth inhibition despite expression of functional receptors. Gynecol Oncol 75: 72.-77, 1999.
28. Hu W, Wu W, Nash MA, Freedman RS, Kavanagh JJ and Verschraegen CF: Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines. Anticancer Res 20: 729-733, 2000. (Pubitemid 30240626)
29. Chang J, Park K, Bang YJ, Kim WS, Kim D and Kim SJ: Expression of transforming growth factor β type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res 57: 2856-2859, 1997. (Pubitemid 27315027)
30. Grady WM, Rajput A, Myeroff L, Liu DF, Kwon K, Willis J and Markowitz S: Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 58: 3101.-3104, 1998.
31. Hahn SA, Schutte M, Hoque AT, et al: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353, 1996.
32. Miyaki M, Iijima T, Konishi M, et al: Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18: 3098-3103, 1999. (Pubitemid 29261230)
33. Eppert K, Scherer SW, Ozcelik H, et al: MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86: 543.-552, 1996.
34. Wang D, Kanuma T, Takama F, et al: Mutation analysis of the smad3 gene in human ovarian cancers. Int J Oncol 15: 949.-953, 1999.
35. Vincent F, Nagashima M, Takenoshita S, Khan MA, Gemma A, Hagiwara K and Bennett WP: Mutation analysis of the transforming growth factor-β type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-β. Oncogene 15: 117-122, 1997. (Pubitemid 27348103)
36. Wang D, Kanuma T, Mizumuma H, Ibuki Y and Takenoshita S: Mutation analysis of the Smad6 and Smad7 gene in human ovarian cancers. Int J Oncol 17: 1087-1091, 2000.
37. Dettke M, Palfi G and Loibner H: Activation-dependent expression of the blood group-related lewis Y antigen on peripheral blood granulocytes. J Leukoc Biol 68: 511-514, 2000.
38. Farhan H, Schuster C, Klinger M, et al: Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen. J Pharmacol Exp Ther 319: 1459-1466, 2006.
39. Wang QY, Zhang Y, Chen HJ, Shen ZH and Chen HL: Alpha 1,3-fucosyltransferase-VII regulates the signaling molecules of the insulin receptor pathway. FEBS J 274: 526-538, 2007. (Pubitemid 46046660)
40. Dowdy SC, Mariani A and Janknecht R: HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor β inhibitor Smad7 via the ETS protein ER81. J Biol Chem 278: 44377-44384, 2003. (Pubitemid 37377186)
41. Ohashi N, Yamamoto T, Uchida C, et al: Transcriptional induction of Smurf2 ubiquitin ligase by TGF-β. FEBS Lett 579: 2557-2563, 2005. (Pubitemid 40615658)
42. Edlund S, Bu S, Schuster N, et al: Transforming growth factor-β1 (TGF-β)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-β-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell 14: 529-544, 2003. (Pubitemid 36237014)
43. Iwai T, Murai J, Yoshikawa H and Tsumaki N: Smad7 inhibits chondrocyte differentiation at multiple steps during endochondral bone formation and down-regulates p38 MAPK pathways. J Biol Chem 283: 27154-27164, 2008.
44. Mazars A, Lallemand F, Prunier C, et al: Evidence for a role of the JNK cascade in Smad7-mediated apoptosis. J Biol Chem 276: 36797-36803, 2001.